Clinical Application of Comprehensive Genomic Profiling Tests for Diffuse Gliomas.

ABSTRACT: Next-generation sequencing-based comprehensive genomic profiling test (CGPT) enables clinicians and patients to access promising molecularly targeted therapeutic agents. Approximately 10% of patients who undergo CGPT receive an appropriate agent. However, its coverage of glioma patients is seldom reported. The aim of this study was to reveal the comprehensive results of CGPT in glioma patients in our institution, especially the clinical actionability. We analyzed the genomic aberrations, tumor mutation burden scores, and microsatellite instability status. The Molecular Tumor Board (MTB) individually recommended a therapeutic agent and suggested further confirmation of germline mutations after considering the results. The results of 65/104 patients with glioma who underwent CGPTs were revie

SUBMITTER: Omura T 

PROVIDER: S-EPMC9139713 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature